Can we measure prior postmenopausal estrogen/progestin use?: The postmenopausal estrogen/progestin interventions trial

American Journal of Epidemiology

Volumn 146, Issue 9, 1997, Pages 763-770

  Greendale, Gail A ^a   James, Margaret K ^b   Espeland, Mark A ^b   Barrett Connor, Elizabeth ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Data collection; Estrogen replacement therapy; Menopause; Progestational hormones; Randomized controlled trials; Recall

Indexed keywords

ESTROGEN; GESTAGEN;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RESEARCH; SELF REPORT;

EID: 0030832650     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009352     Document Type: Article

References (19)

1. Ernster VL, Bush TL, Higgins GR, et al. Benefits and risks of menopausal estrogen and/or progestin hormone use. Prev Med 1988;17:201-23.
2. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
3. Rodriguez C, Calle EE, Coates RJ, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:828-35.
4. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to rent and discontinued use of conjugated estrogens. N Engl J Med 1985;313:969-72.
5. Hulka BS, Chambless LE, Deubner DC, et al. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 1982;143:638-44.
6. Kreiger N, Marrett LD, Clarke EA, et al. Risk factors for adenomatous endometrial hyperplasia: case control study. Am J Epidemiol 1986;123:291-301.
7. Persson I, Bergkvist L, Adami H-O. Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. Int J Epidemiol 1987;16:222-8.
8. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116:114-22.
9. Goodman MT, Nomura AMY, Wilkens LR, et al. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 1990;131:815-25.
10. Jannausch ML, Sowers MFR. Consistency of perimenopausal estrogen use reporting by women in a population-based prospective study. Maturitas 1992;14:161-9.
11. Espeland MA, Bush TL, Mebane-Sims I, et al. Rationale, design, and conduct of the PEPI Trial. Control Clin Trials 1995;16(4Suppl):3S-19S.
12. Johnson S, Mebane-Sims I, Hogan PE, et al. Recruitment of postmenopausal women in the PEPI Trial. Control Clin Trials 1995;16(4Suppl):20S-35S.
13. Wood PD, Kessler G, Lippel K, et al. Physical and laboratory measurements in the PEPI Trial. Control Clin Trials 1995;16(4 Suppl):36S-53S.
14. Miller VT, Byington RL, Espeland MA, et al. Baseline characteristics of the PEPI participants. Control Clin Trials 1995;16(4Suppl):54S-65S.
15. SAS Institute. SAS procedure guide, version 6, 3rd ed. Cary NC: SAS Institute Inc, 1990.
16. Espeland M, Hui S. A general approach to analyzing epidemiologic data that contain misclassification errors. Biometrics 1987;43:1001-12.
17. Espeland MA, Handelman SL. Using latent structure models to characterize and assess relative error in discrete measurements. Biometrics 1989;45:587-600.
18. Goodman LA. The multivariate analysis of qualitative data: interaction among multiple classifications. J Am Stat Assoc 1970;65:226-56.
19. Beresford SAA, Coker AL. Pictorially assisted recall of past hormone use in case-control studies. Am J Epidemiol 1989;130:202-5.